Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03198052 Not yet recruiting - Cancer Clinical Trials

PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The third generation of CAR-T cells that target PSCA, MUC1, PD-L1, or CD80/86 have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with PSCA, MUC1, PD-L1, or/and CD80/86 expressions.In this phase I study, the safety,tolerance, and preliminary efficacy of the PSCA/MUC1/PD-L1/CD80/86-CAR-T cell immunotherapy on human cancers will firstly be tested.

NCT ID: NCT03192501 Not yet recruiting - Cancer Clinical Trials

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care

Start date: July 1, 2017
Phase: N/A
Study type: Observational

This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care in progress free survival (PFS),overall survival (OS),and improvement of life quality.

NCT ID: NCT03186703 Not yet recruiting - Cancer Clinical Trials

Evaluating the Impact of the McMaster Optimal Aging Portal on Cancer Prevention Behaviours in Underserved Populations

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The goal of the McMaster Optimal Aging Portal is to be a trustworthy source for health information. The Portal team can see (through measuring analytics of website use) that thousands of people are using the Portal and the knowledge-sharing strategies in place (email alerts, Twitter and Facebook), with many more users added each month. Previous studies have measured the quality and trustworthiness of health information available online; others have studied the numbers and populations who use different types of information and how easy it is to use and understand. This study builds on that knowledge to find out: if easy-to-understand evidence-based messages reach members of the public, do these messages change what people know and think to do to stay healthy (in this case, what they know and think to do to lower their risk of cancer)?

NCT ID: NCT03186404 Not yet recruiting - Cancer Clinical Trials

Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study

SPARE-HF
Start date: July 2017
Phase: Phase 2
Study type: Interventional

Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF). Current standard of care for preventing AC induced HF (AIHF) is cardiac surveillance followed by initiation of treatment once HF is diagnosed. With this approach 89% of patients fail to recover heart function and 46% will experience adverse cardiac events. Therefore there is a need for effective preventive therapy to reduce the risk of AIHF. Based on small human studies, animal studies, and our own pilot data, statins are an ideal class of drug for this purpose. We will conduct a pilot double blinded, placebo controlled, randomized controlled trial to assess whether pre-treatment with statins before AC can prevent heart dysfunction. Eligible patients with cardiovascular risk factors scheduled to receive AC will be recruited. They will be randomized to statin therapy or placebo and followed until the end of cancer treatment. Primary outcome is the difference in cardiac MRI-determined left ventricular ejection fraction between pre-AC and end of treatment.

NCT ID: NCT03173833 Not yet recruiting - Cancer Clinical Trials

Fulfilling Care Needs of Adolescents With Cancer

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The aim of phase 1 of this study is to develop a care need scale (CNS) for adolescents with cancer. The aim of phase 2 is to examine the mediating role of care needs between physical and psychosocial dysfunction and QoL, and to explore the recovery trajectory and its predictors regarding the care needs, physical and psychosocial factors, and the QoL of adolescents with cancer at the first, second, and third 3-month periods after initiating on-treatment and off-treatment. The aim of phase 3 is to examine the effectiveness of the computerized assessment with graphic outcome (CAGO) for fulfilling the care needs of adolescents with cancer, its acceptability for adolescents with cancer, and its usability for clinicians in pediatric oncology units.

NCT ID: NCT03167372 Not yet recruiting - Depression Clinical Trials

Pilot N-of-1 Light Therapy Study

Start date: July 2017
Phase: N/A
Study type: Interventional

This study compares the effect of two N-of-1 trials on study compliance with an N-of-1 protocol and on satisfaction with participation in an N-of-1 trial. Using within-person analyses, the study also compares the effect of different types of light therapy on mood, fatigue, sleep, physical activity, and side effects within a mild to moderately depressed cancer survivor population. Twenty participants will be randomized to the bright white versus dim red light therapyN-of-1 trial, while the remaining 10 participants will be randomized to a dim white versus dim red light comparator N-of-1 trial.

NCT ID: NCT03154671 Not yet recruiting - Cancer Clinical Trials

Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

A multicentre two-group parallel single-blind (outcome assessor) randomized controlled trial (RCT). A cost effectiveness study alongside a clinical trial using a payer and societal perspective to study the cost-effectiveness of geriatric assessment and management compared to usual care will be conducted. Participants allocated to the control group will receive usual oncology care. Participants allocated to the intervention group will receive a comprehensive geriatric assessment and management in addition to their usual oncology care. The intervention will take 6 months to be completed. Total study follow-up will be 12 months for each participant.

NCT ID: NCT03153618 Not yet recruiting - Cancer Clinical Trials

VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine

VALIDATE
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The collection and analysis of family, medical, lifestyle, and environmental exposure history (a Comprehensive Health History or "CHH") can identify critical risk factors for many chronic and life-threatening conditions, including cancer. Despite its importance, CHH is infrequently documented and analyzed in primary-care medical practice due to numerous hurdles, and currently available tools have proven inadequate to address this critical problem. This study will evaluate the Virtual Agent Linked Intelligent Disease Assessment Tool Engine ("VALIDATE") system as an easy to administer, accurate, cost-effective, and clinically useful tool for collecting and analyzing structured CHH data.

NCT ID: NCT03148418 Not yet recruiting - Cancer Clinical Trials

A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Start date: August 5, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be according to the respective parent study. Study treatment in the extension study can continue until disease progression or beyond if the participant continues to derive clinical benefit in the judgment of the investigator and if allowed by the parent study or local prescribing information, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.

NCT ID: NCT03146806 Not yet recruiting - Pain Clinical Trials

Intranasal (NAS) Ketamine for Cancer Pain

Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine the safety, feasibility, and utility of intranasal (NAS) ketamine in persistent uncontrolled cancer related pain. In this prospective clinical trial the researchers will investigate the use of NAS ketamine in patients with pain related to cancer or cancer treatment. The researchers plan to enroll at least 15 patients meeting inclusion/exclusion criteria, to achieve a minimum of 10 patients who complete the study. Participants will be recruited from the supportive oncology clinic, oncology clinics, the pain clinic and Acute Pain Service at Emory. Participants will be asked to return to the Phase I unit of the Winship Cancer Building C for a total of 5 study visits, each two to five days apart. During these visits participants will complete questionnaires, have blood samples drawn and will have study medication administered to them in escalating doses. For safety monitoring participants will be contacted by telephone 14 days after the last dose of medication administered.